Ticker Symbol: CUR
Aug. 31, 2012
/PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a
life sciences company that develops and commercializes high-value cancer diagnostic tests, announced today that the Company will release its third quarter results on
September 6, 2012
, at about
4:30 p.m. (EDT)
the same day, management will hold a conference call with investors to discuss these results.
Investors and financial analysts wishing to participate in the "DiagnoCure Q3 2012 Earnings Announcement" conference call shall dial the toll-free number 1-888-231-8191, and provide the conference ID number: 11370258.
The event will also be webcasted live on DiagnoCure's website at
, through the hyperlink under the "Presentations" page of the "Investors" tab. A replay of the audio conference will be available on
September 10, 2012
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company launched the Previstage
GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in
. The Company has also granted a worldwide exclusive license agreement to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (HOLX:NASDAQ) operating as Hologic Gen-Probe, for the development and commercialization of a third-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA® PCA3 test is commercialized in
under CE mark and is approved for commercialization in
the United States
. For more information, visit
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.